Vulvar Paget Disease: One Century After First Reported.

This is the author's manuscript

Original Citation:
Vulvar Paget Disease: One Century After First Reported. / PRETI M; MICHELETTI L; M. MASSOBROIO; ANSAI SI; WILKINSON EJ. - In: JOURNAL OF LOWER GENITAL TRACT DISEASES. - ISSN 1089-2591. - 7(2)(2003), pp. 122-135.

Availability:
This version is available http://hdl.handle.net/2318/39322 since

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Vulvar Paget Disease: One Century After First Reported

Mario Preti, MD,1 Leonardo Micheletti, MD,1 Marco Massobrio, MD,1 Shin-ichi Ansai, MD, PhD,2 and Edward J. Wilkinson, MD3
1Department of Gynecology and Obstetrics, University of Turin, Turin, Italy; 2Department of Dermatology, Akita University School of Medicine, Akita City, Japan; and 3Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL

Abstract

Objectives. To provide a critical assessment of the published literature on vulvar Paget disease and to allow individualized approaches to affected patients.

Materials and Methods. A computerized search for studies published in the literature up to June 2002 was carried out using Ovid® and Medline databases. We excluded single case reports, letters to editors, and abstracts.

Results. Historical and epidemiological aspects of vulvar Paget disease are summarized. Clinical and histopathological data support a recent proposal to classify vulvar Paget disease into two categories, primary and secondary, with significant clinical and prognostic implications. The treatment for primary vulvar Paget disease is wide and deep surgical excision. Inguinofemoral lymphadenectomy is added in the management of invasive neoplasms. In the presence of secondary Paget disease, therapy must be directed toward treatment of associated carcinoma.

Conclusions. The subclassification of vulvar Paget disease is essential for correct clinical management and treatment. Immunohistochemistry may assist in this important distinction.

Key Words: vulvar Paget disease, immunohistochemistry

Extramammary Paget disease is a group of rare cutaneous neoplasms with different localization and natural history [1]. In 1874 Sir James Paget, describing the disease of the breast that now bears his name, alluded to the possibility that the same entity might also involve other parts of the body [2]. The occurrence of extramammary Paget disease involving the penis and scrotum was first reported in 1888 by Crocker [3], for the perineal and anal region along with the scrotum by Darier and Couillaud in 1893 [4], and in 1901 Dubreuilh published the first instance of vulvar Paget disease in the British Journal of Dermatology [5].

Extramammary Paget disease is primarily a women’s disease, with men constituting approximately 20% of cases. Lesions are usually found in sites with a high density of apocrine glands: vulva, penis, scrotum, anus, perianal region, and axilla. Other regions where apocrine or modified apocrine sweat glands are located, such as Moll’s glands of the eyelids and ceruminous glands of the external ear canal, may be extramammary Paget disease sites. The term “ectopic” extramammary Paget disease [6] has been applied to locations where apocrine glands are not usually found, such as the buttck, the lateral aspect of the back, or the lower portion of the chest.

The most common location for extramammary Paget disease in women is the vulva; more than 600 cases have been reported to date. The second most common site is the perianal region. Simultaneous presentations at distant sites are rare [7, 8].

Intraepithelial vulvar Paget disease was classified as a...
nonsquamous intraepithelial neoplasia of the vulva by
the International Society for the Study of Vulvar Disease
Terminology Committee in 1986 [9].

OBJECTIVE

The rarity of vulvar Paget disease makes it difficult to
understand its different clinicopathological and prognos-
tic characteristics from a single reported series. A
critical assessment of the studies on vulvar Paget disease
was carried out to update diagnostic concepts and to
allow individualized management strategies of affected
patients.

SOURCES, STUDIES SELECTION,
AND INTEGRATION

We conducted a computerized search using Ovid©
(Ovid Technologies©, Inc., New York, NY) and
line database for studies published from January 1966
to June 2002 with the search terms “Paget disease.”
References were limited to studies published in English,
pertaining to humans, and more specifically females. A
cross search using the terms “vulvar neoplasms and per-
ineum” was performed to avoid the inclusion of Paget
disease of sites other than the vulvoperineal region. We
excluded single case reports, letters to editors, and ab-
stracts. Evaluation of the bibliographies of retrieved ar-
ticles and consultation with experts in the field provided
additional references.

Relevant features were extracted from each study and
divided into the following groups: clinical aspects, his-
topathological aspects, vulvar Paget disease and invasive
neoplasms, and treatment. The review was focused on
data useful to optimize patient care.

CLINICAL ASPECTS

Patient Characteristics

Vulvar Paget disease is uncommon and accounts for
2.5% of all vulvar malignancies [10]. It affects mainly
white patients aged between 40 and 80 years. The me-
dian age is approximately 70 [10–13] both for intraep-
ithelial and invasive vulvar Paget disease patients [14].
No element in patients’ family, environmental, or social
histories suggested an etiology or propensity for devel-
oping vulvar Paget disease.

Symptomatology

Symptoms are not specific; most patients report itch-
ing, burning, and soreness. A small subset of patients
may be asymptomatic. Presence of vulvar pain, bleed-
ing, and tumor formation are reported to be more com-
mon in patients affected by invasive disease [14, 15].

Macroscopic Appearance

Vulvar Paget disease presents as a variety of clinical
lesions that may occur over a protracted course. Initially
it is velvety, soft, and red or bright pink with scattered
white islands of hyperkeratosis (Figure 1). The lesions
become erythematous, plaque like, and desquamating
especially when located in dry areas. Rarely the appear-
ance is ulcerated (Figure 2). Cases of pigmented vulvar
Paget disease are reported [16]. The borders appear ir-
regular, slightly elevated, and sharply demarcated [17,
18]. The visible borders of vulvar Paget disease are often
misleading as Paget cells may spread along the basal
layers of normal appearing skin with multicentric foci
[18–22]. Involvement may be extensive including the
perianal region, genitocrural, and inguinal folds [23].
Clinical examination should determine the presence of
periurethral and perianal lesions (Figure 3). In these
cases an involvement of the skin by a noncutaneous
internal neoplasm may occur (see below).

Figure 1. Clinical aspect of intraepithelial primary vulvar Paget
disease: an extensive erythematous slightly raised lesion with ar-
areas of hyperkeratosis involves the external genitalia and the
right genitocrural fold.
Differential Diagnosis

Macroscopic aspects of vulvar Paget disease lesions are often confused with lichen sclerosus, dermatophytosis, candidiasis, contact dermatitis, psoriasis, seborrheic dermatitis, and squamous vulvar intraepithelial neoplasia. An accurate anamnesis, a clinical examination to search for similar lesions elsewhere on the body and a biopsy with the appropriate use of immunohistochemistry, will confirm a vulvar Paget disease diagnosis.

HISTOPATHOLOGICAL ASPECTS

Histogenesis

Among the theories discussed in the literature regarding the histogenesis of vulvar Paget disease [11, 24, 25] the multifocal origin was generally accepted. This assumption was based on concepts of skin embryology. Woodruff and Kaufman hypothesized that Paget cells derive from undifferentiated basal cells of the stratum germinativum [26, 27], the stem cells that, except for the melanocytes, are the origin of all the cells of the epidermis and its appendages [28]. This embryology-based hypothesis explained the multifocal primary origin of intraepithelial Paget disease with or without associated underlying adenocarcinoma and does not contradict the fact that intraepithelial disease can remain in situ for a long period of time before invading the dermis [17, 24, 25, 29, 30].

The origin of vulvar Paget disease from supernumerary mammary glands has also been suggested [31]. Current evidence, however, supports that these mammary-like glands are not supernumerary mammary glands but rather vulvar specialized anogenital glands closely related to eccrine glands [32].

Recently Wilkinson and Brown have proposed a classification of vulvar Paget disease that takes into account its heterogenous origin. This classification defines two distinct groups of vulvar Paget disease, those of cutaneous origin and those of noncutaneous origin. The latter group includes Paget disease of urothelial, anorectal, and other noncutaneous sites [33]. This classification is supported by immunohistochemical studies to distinguish these Paget lesions and aids in understanding the otherwise apparent conflicting findings in various reports of Paget disease.

Histopathology

Vulvar Paget disease diagnosis is established through the histologic examination of a biopsy. Pathognomonic is the finding of atypical glandular type cells, the Paget cells, scattered or grouped in nests within the surface squamous epithelium [34, 35]. In routine hematoxylin and eosin stained histologic sections, Paget cells are rounded or polygonal elements of relatively large size with abundant clear pale eosinophilic cytoplasm (Figure 2).
The cytoplasm contains neutral and acid mucopolysaccharides that stain positively with mucicarmine, aldehyde fuchsin, Alcian blue at pH 2.5, Periodic acid/Schiff, which is resistant to diastase digestion [17, 36], and it is usually also positive to colloidal iron and sialomucin staining [37]. Mitotic figures do not frequently occur [38].

Involvement of the pilosebaceous units and sweat glands may be seen [34, 39–41]. The occurrence of epidermal lesions adjacent to anogenital Paget disease has been recently studied [42].

As opposed to intraepithelial vulvar Paget disease, invasive disease shows a discontinuous basement membrane in the area of invasion with groups of Paget cells protruding into the underlying stroma [38]. These cells appear more anaplastic and react weakly with mucicarmine stain [39, 41].

Differential Diagnosis

Histologic differential diagnosis of vulvar Paget disease includes pagetoid melanoma, vulvar squamous intraepithelial neoplasia, sebaceous carcinoma, Merkel cell carcinoma with pagetoid intraepidermal spread, eccrine porocarcinoma, tricholemmal carcinoma, cutaneous T-cell lymphoma, Pagetoid Spitz nevus, and histiocytosis X [43–45].

It is crucial to exclude stromal invasion, underlying invasive adenocarcinoma, and vulvar pagetoid spread of associated adjacent noncutaneous adenocarcinoma that severely affect patients’ prognosis. On routine histology some differences can be found between Paget cells of primary vulvar cutaneous origin and those of anorectal and urothelial origin, with secondary vulvar spread [33]. Immunohistochemistry will help in the diagnosis.

Immunohistochemistry

The immunohistochemical characteristics of Paget cells in primary intraepithelial vulvar Paget disease are summarized in Table 1 together with the characteristics of normal skin [24, 29, 43, 46–53]. From these findings, intraepidermal Paget cells are proved to be differentiated mainly toward the ductal portion (CEA, II-7, B6.2 positivity), although in some instances partially toward the secretory portion of the sweat glands (GCDFP-15, CD15, PKK1 positivity). The question of whether Paget cells show apocrine differentiation is still controversial, but they do not show complete apocrine differentiation nor do they show eccrine differentiation.

Immunohistochemistry provides reliable assistance in the differential diagnosis of vulvar Paget disease against pagetoid melanoma using S100 (a calcium-binding protein), HMB45 (a melanoma-specific cytoplasmic antigen), and Melan-A as melanocytic markers [16, 54–56] and against vulvar squamous intraepithelial neoplasia as the panel of keratins expressed by Paget cells differs from the cells of adjacent epidermis [57]. In particular the strong immunoreactivity for keratins 7 and 19 facilitates the identification of small foci of intraepithelial and invasive vulvar Paget disease lesions [58–60].

Data from the literature underline that Paget cells in primary cutaneous vulvar Paget disease are for the most part immunoreactive for cytokeratin 7, CEA, and GCDFP-15 (Figure 5). Less frequently they are focally reactive for cytokeratin 20. This immunophenotype (CK 7+, CK 20+/+, GCDFP 15+) assists in the distinction between primary vulvar Paget disease and less common pagetoid involvement of vulvar skin by a noncutaneous internal neoplasm. This distinction is of utmost clinical importance as therapeutic approaches and prognoses of these diseases are quite different, despite their similar clinical and routine histopathologic findings.

The most common cause of noncutaneous vulvar pagetoid involvement is perianal spread from an associated anorectal adenocarcinoma. These cases, different from primary vulvar Paget disease, typically express cytokeratin 20 and, at the same time, immunohistochemical reactions for GCDFP15 are negative [57, 60–72].

The second most common cause of noncutaneous Paget disease is related to direct extension or intraepithelial epidermotropic extension to the vulvar skin or

![Figure 4. Histologic aspect of intraepithelial primary vulvar Paget disease: typical Paget's cells are present singly and clustered in nests throughout the whole thickness of the epidermis. The pale cytoplasm easily differentiates them from surrounding keratinocytes (hematoxylin and eosin, original magnification ×40).](image)
mucosa by urothelial neoplasia (Paget disease secondary to transitional cell carcinoma of the bladder or urethra, also referred to as pagetoid intraepithelial urothelial neoplasia) [33, 71, 73–76]. The cells of urothelial origin are not GCDFP-15 positive as are the Paget cells of primary cutaneous vulvar Paget disease, but they are immunoreactive for cytokeratin 7 and often for cytokeratin 20 and Uroplakin III like transitional cell carcinomas of the urinary tract [71, 77–80]. Immunoreactivity for Uroplakin III was not found in any cases of primary cutaneous vulvar disease [80].

Other cases of vulvar secondary involvement from adenocarcinoma of the cervix, endometrium, and ovary are described as single case reports.

Electron Microscopy

Electron microscopy shows that vulvar Paget disease cells differ markedly in structure from the keratinocytes of the surrounding epidermis, and cell cytoplasm appears more electron lucent. Two cell variants are present, secretory and nonsecretory, the former being more common with abundant secretory granules, well-developed Golgi complex, and profiles of endoplasmic reticulum. A small number of cells do not contain se-
cretory vacuoles and have scanty cytoplasmic organelles [29, 81]. Cells of invasive vulvar Paget disease show the same features as those of intraepithelial vulvar Paget disease, with fewer secretory granules. Small desmosomes, which attach Paget cells to each other and to adjacent keratinocytes, are absent in invasive neoplasms [41, 81]. These findings are consistent with the recent report of reduced expression of desmoglein I and plakoglobin (cell-cell adhesion molecules) in invasive vulvar Paget disease [82].

**DNA Ploidy**

The prognostic role of ploidy in vulvar Paget disease has been analyzed in four different series [59, 83–85]. Twenty-five of 59 cases of intraepithelial vulvar Paget disease (42%) were nondiploid and 8 of 21 invasive lesions (38%) were diploid. The recurrence rate was 26% (11/42) in diploid lesions and 31% (12/38) in nondiploid lesions. From these data we cannot infer a significant value of tumor DNA ploidy in predicting either recurrence or invasion.

**Viruses, Oncogenes, and Tumor Markers**

Some of the characteristics of vulvar Paget disease, such as multicentricity, a tendency to recur, and rare invasiveness, recall virus-associated epithelial atypia. No study has evidenced human papillomavirus (HPV) antigen or HPV DNA in the cells of vulvar Paget disease specimens [42, 86–89], so that the participation of HPV infection in the pathogenesis of the disease is unlikely. On the other hand neither p53 gene mutations nor loss of heterozygosity at selected loci were detected in Paget cells [89]. Immunohistochemical analyses for c-erb-B2 antigen [22, 30, 90], bcl2, and p53 protein expression [59, 84, 91, 92] have revealed conflicting and inconclusive results. The role of these oncogenes is still undetermined and without an actual role in indicating patients at greater risk of recurrence or invasive neoplasm. No data support the use of serum tumor markers SCC, LSA, and Ca 19–9 to predict disease occurrence or recurrence [93].

The underlying genetic defects in extramammary Paget disease are probably different from those in other epithelial malignancies. Further molecular genetic studies may help to cast light on the peculiar biological behavior of vulvar Paget disease.

**VULVAR PAGET DISEASE PROPOSED SUBCLASSIFICATION**

Wilkinson and Brown have applied data on histogenesis, histopathological, and immunohistochemical methods as well as clinical features to subclassify vulvar Paget disease into two main categories [33].

1. **PRIMARY (of cutaneous origin) vulvar Paget disease** is subclassified:
   1a) Paget disease as a primary intraepithelial neoplasm
   1b) Paget disease as an intraepithelial neoplasm with stromal invasion
   1c) Paget disease as a manifestation of an underlying primary adenocarcinoma of a skin appendage or a subcutaneous vulvar gland

2. **SECONDARY vulvar Paget disease** (involvement of the vulvar skin by a noncutaneous internal neoplasm) is subclassified in:
   2a) Paget disease secondary to anal or rectal adenocarcinoma
   2b) Paget disease secondary to urothelial neoplasia
   2c) Paget disease secondary to adenocarcinomas or related tumors of other sites

The following paragraphs will illustrate the clinical and pathological importance of distinction between the different vulvar Paget lesions.

**VULVAR PAGET DISEASE AND INVASIVE NEOPLASMS**

In the past decades there was considerable confusion about the relationship between vulvar Paget disease and associated malignancies. This term has been used to indicate: 1) the presence of dermal invasion; 2) association with underlying skin appendage invasive adenocarcinoma; and 3) association with carcinoma of adjacent structures (vulva-vagina), regional internal organ (colon-rectum, urinary tract), unrelated visceral organ (uterus, ovary, stomach), or carcinomas at a distant site (breast, lung) occurring before, contemporaneously, or after vulvar Paget disease diagnosis.

In Table 2 the studies where a distinction among the above-cited subgroups was feasible are reported [11, 13–15, 20, 23, 24, 35, 39–41, 59, 66, 67, 83–85, 93–105].
Primary Vulvar Paget Disease with Stromal Invasion

Dermal invasion may evolve from primary vulvar intraepithelial Paget disease over time. The subset of minimally invasive vulvar Paget disease (stromal invasion ≤ 1 mm) [20, 104] represents direct histologic evidence that intraepithelial vulvar Paget disease has the potential to invade as intraepithelial and that invasive components are composed of the same cells with identical immunophenotype [59]. The development of invasive vulvar Paget disease is reported up to 10 years after initial treatment for intraepithelial vulvar Paget disease [20]. In most invasive vulvar Paget disease an extensive intraepithelial skin involvement (≥ 10 cm in diameter) is reported [13], and invasion does appear to develop in an undifferentiated area of intraepithelial disease [106].

The differing proportion of invasive vulvar Paget disease in the various series (from 0% to 48%) (Table 2) may reflect referral bias of cases more likely to be referred to tertiary centers. Furthermore the identification of invasive disease may be a result of more thorough histologic sampling of the tumor [59].

Vulvar Paget Disease as a Manifestation of Primary Underlying Adenocarcinoma of the Vulva

In mammary Paget disease almost all cases reflect the extension of malignant cells into the epidermis, via lactiferous ducts, from an underlying mammary carcinoma: the so-called epidermotropic metastasis [1]. This relationship is generally absent in vulvar Paget disease and association with invasive underlying adenocarcinoma is present in approximately 10% of cases (range = 0–40%) (Table 2). Selection bias in different series may result from the differing surgical procedures used. Wide vulvar excision may underestimate the presence of underlying adenocarcinoma with respect to total vulvectomy. A more reliable prevalence of concurrent adenocarcinoma

Table 2. Vulvar Paget Disease: Stromal Invasion, Association with Underlying Adenocarcinomas, and Other Carcinomas Reported in the Literature

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Cases</th>
<th>No. of Cases with Stromal Invasion</th>
<th>No. Cases with Underlying Adenocarcinomas</th>
<th>No. Cases with Other Carcinomas</th>
<th>Site%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koss</td>
<td>1968</td>
<td>8</td>
<td>0</td>
<td>25</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Fenn</td>
<td>1971</td>
<td>7</td>
<td>2</td>
<td>29</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Creasman</td>
<td>1975</td>
<td>15</td>
<td>0</td>
<td>33</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Taylor</td>
<td>1975</td>
<td>18</td>
<td>4</td>
<td>22</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Tsukada</td>
<td>1975</td>
<td>8</td>
<td>0</td>
<td>13</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Lee</td>
<td>1977</td>
<td>13</td>
<td>1</td>
<td>8</td>
<td>23</td>
<td>1</td>
</tr>
<tr>
<td>Breen</td>
<td>1978</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Stacy</td>
<td>1986</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Bergen</td>
<td>1989</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Curtin</td>
<td>1990</td>
<td>36</td>
<td>1</td>
<td>3</td>
<td>9</td>
<td>25</td>
</tr>
<tr>
<td>Feuer</td>
<td>1990</td>
<td>19</td>
<td>2</td>
<td>11</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Ewing</td>
<td>1991</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>17</td>
<td>0</td>
</tr>
<tr>
<td>Olson</td>
<td>1991</td>
<td>16</td>
<td>6</td>
<td>38</td>
<td>3</td>
<td>19</td>
</tr>
<tr>
<td>Garzetti</td>
<td>1992</td>
<td>4</td>
<td>1</td>
<td>25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Helm</td>
<td>1992</td>
<td>21</td>
<td>0</td>
<td>2</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Molinie</td>
<td>1993</td>
<td>36</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Baehrendtz</td>
<td>1994</td>
<td>28</td>
<td>3</td>
<td>11</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Cotton</td>
<td>1995</td>
<td>14</td>
<td>2</td>
<td>14</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>Fishman</td>
<td>1995</td>
<td>14</td>
<td>1</td>
<td>7</td>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>Kodama</td>
<td>1995</td>
<td>30</td>
<td>9</td>
<td>30</td>
<td>11</td>
<td>37</td>
</tr>
<tr>
<td>Kohler</td>
<td>1996</td>
<td>19</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>Tsai</td>
<td>1996</td>
<td>5</td>
<td>1</td>
<td>20</td>
<td>2</td>
<td>40</td>
</tr>
<tr>
<td>Goldblum</td>
<td>1997</td>
<td>19</td>
<td>6</td>
<td>32</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Scheistuen</td>
<td>1997</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td>Taganji</td>
<td>1997</td>
<td>16</td>
<td>2</td>
<td>13</td>
<td>5</td>
<td>31</td>
</tr>
<tr>
<td>Crawford</td>
<td>1999</td>
<td>21</td>
<td>10</td>
<td>48</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Fanning</td>
<td>1999</td>
<td>100</td>
<td>12</td>
<td>12</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td>Piura</td>
<td>1999</td>
<td>5</td>
<td>1</td>
<td>20</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>Parker</td>
<td>2000</td>
<td>76</td>
<td>9</td>
<td>12</td>
<td>13</td>
<td>17</td>
</tr>
<tr>
<td>Zollo</td>
<td>2000</td>
<td>22</td>
<td>6</td>
<td>27</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>21</td>
<td>660</td>
<td>79</td>
<td>12</td>
<td>72</td>
<td>11</td>
</tr>
</tbody>
</table>

Total: 650, No. cases with Stromal Invasion: 79, No. cases with Underlying Adenocarcinomas: 12, No. cases with Other Carcinomas: 72, Colon: 43, Urinary tract: 1, Ovary: 1, Uterus: 1, Vulva: 1, Vagina: 38, Breast: 38, Other: 38

*At diagnosis or during follow-up for intraepithelial disease.

*Vulvar Paget disease as a manifestation of an underlying primary adenocarcinoma of a skin appendage or a subcutaneous vulvar gland.

*Occurring before, contemporaneously, or after vulvar Paget disease diagnosis.

*Multiple sites in the same patients are reported, sites are not specified in some studies.
carcinoma (4%) may be reported from large series where all surgical procedures were included [13]. Furthermore some reports showing a high prevalence of underlying adenocarcinoma may have included cases of invasive vulvar Paget disease.

Primary underlying vulvar adenocarcinoma may originate from adenocarcinoma of the Bartholin gland, specialized anogenital glands, or other vulvar glandular structures. Underlying adenocarcinomas are usually clinically apparent. However, this is not invariable [20], and thus the underlying dermis, beneath the clinically visible Paget disease, should be removed for appropriate histologic evaluation.

Association with Other Neoplasms

Patients with vulvar Paget disease are also reported to be at increased risk of other primary neoplasms. The list of associated malignancies includes anal, rectal, colonic, endometrial, cervical ovarian and stomach adenocarcinoma, vaginal and vulvar squamous cell carcinoma, papillary transitional cell carcinoma of the renal pelvis, ureter, bladder and urethra, basal cell skin cancer, lung, breast, and thyroid carcinoma. The reported frequency of associated malignancy is highly variable by site, type, and temporal relationship, and it ranges from 0% to 50% (mean 20%) (Table 2). The prevalence of cancer in these elderly patients is not significantly different from published data for patients from their demographic group [107], and the association of vulvar Paget disease with cancer may be, for the most part, a secondary effect of the advanced age of these patients [13]. To truly evaluate whether the risk of another malignancy in women with Paget disease is increased, one would need to design a specific study to address this hypothesis. Moreover, the search for additional malignancy would have to be systematic, which it was not in most parts of the series examined.

It should be stressed that perianal or periurethral Paget disease may represent involvement of the vulvar skin by pagetoid extension of a regional neoplasm including anorectal adenocarcinoma or urothelial neoplasia. In these cases of secondary vulvar Paget disease immunohistochemical analysis demonstrates distinctive features.

A systemic work-up for an associated malignancy should be reserved for selected cases. An evaluation including colon-sigmoidoscopy, urethrocytoscopy, chest roentgenogram, intravenous pyelogram, mammogram, cervicovaginal Pap smear, urine cytology, and CAT scan [101] appears too extensive to be applied routinely to patients with only vulvar localization of Paget disease.

TREATMENT

Ideal therapy aims at minimal tissue destruction and low recurrence rate, but some features of vulvar Paget disease interfere with these goals. The treatment and prognosis are closely related to pathologic characteristics of the disease.

Primary Vulvar Intraepithelial Paget Disease

The treatment is wide and deep surgical excision as recommended by most authors [23, 25, 93, 108]. Wide local excision, including a peripheral margin of 1.5–2 cm of skin with normal appearance, is not always easy to achieve while preserving sexual function, normal anatomy, and body image, particularly for excision of lesions at the vaginal side near the urethral orifice. At the same time, deep resection of the lesion is mandatory. Not only the dermis but also all skin appendages that could potentially contain Paget cells should be resected. As no hair follicles or sweat glands extend more than 4.0 mm below the surface of the epidermis [23], excision deeper than this is not recommended. Complete inclusion of skin appendages and histologic examination to search for underlying neoplasms are two reasons that exclude laser vaporization as the sole treatment of vulvar Paget disease [98, 109, 110]. Recently photodynamic therapy [111] has been proposed as a primary treatment of vulvar Paget disease using topical 20% 5-aminolevulinic acid and Argon dye laser [105].

Primary Vulvar Paget Disease with Stromal Invasion

Most studies have reported that foci of superficial dermal invasion associated with predominantly intraepithelial vulvar Paget disease did not adversely affect prognosis [14, 20, 59, 67]. The rare reports of metastatic minimally invasive vulvar Paget disease probably describe un-sampled deeper foci of invasion [20, 104] and, up to now, a conservative approach in the treatment of minimally invasive vulvar Paget disease is recommended. It should be emphasized that in the literature there is no consensus for the method of measurement for depth of invasion in vulvar adenocarcinoma.

Vulvar Paget Disease as a Manifestation of an Underlying Primary Cutaneous Adenocarcinoma of the Vulva

These patients, as well as patients with stromal invasion exceeding 1 mm, should be treated with vulvar excision to the fascia of the clinically involved area and
bilateral inguinofemoral lymphadenectomy. The clinical course of these patients is much different from intraepithelial vulvar Paget disease. They recur soon after the initial treatment, frequently showing general metastases [14]. It is clear that surgical treatment alone is not enough for these patients because micrometastases seem to exist at the time of surgical excision [14, 94]. For these patients effective systemic therapy is indicated.

**Vulvar Paget Disease as Involvement of the Vulvar Skin by a Noncutaneous Internal Neoplasm**

In such cases therapy is directed toward treatment of the associated carcinoma, and vulvar Paget disease can be treated with a conservative approach like an intraepithelial lesion. The prognosis depends on the stage and prognostic factors of the associated adenocarcinoma.

**Integrated Therapies**

There are few data in the literature on radiotherapeutic or chemotherapeutic approaches to locally advanced, recurred, or invasive vulvar Paget disease. The small number of patients treated with chemotherapy (topical bleomycin, mitomycin-C, 5-fluorouracil, cyclophosphamide, doxorubicin, cisplatin, carboplatin, vincristine) as yet allows for no final conclusions about the regimens proposed [14, 112]. Clear inclusion criteria and adequate follow-up time are required to clarify the role of radiation therapy for patients who are not surgical candidates [113–115]. The clinical evidence does not support the use of chemotherapy and radiotherapy for patients with intraepithelial vulvar Paget disease not associated with invasive carcinoma.

A recent study demonstrated that vulvar Paget disease cells express androgen receptors rather than estrogen or progesterone receptors [116]. Further studies are needed to determine whether androgen receptor status could aid in the therapy of recurrent and invasive vulvar Paget disease.

**Margin Control**

In primary vulvar Paget disease the clinical visible borders do not completely define the histologically involved area. Therefore a balance between the extent of surgical resection and the probability of leaving Paget cells in the remaining vulvar tissue is difficult to determine. Various types of margin controls have been proposed to reduce local recurrence, including colposcopi-

### Table 3. Intraepithelial Vulvar Paget Disease and Local Recurrence after Therapy (not considered patients lost to follow-up or that refused primary treatment)

<table>
<thead>
<tr>
<th>Author</th>
<th>Ref.</th>
<th>year</th>
<th>No. of cases</th>
<th>No. cases recurred</th>
<th>% Recurrences</th>
<th>No. cases dead of disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koss</td>
<td>[39]</td>
<td>1968</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fenn</td>
<td>[35]</td>
<td>1971</td>
<td>7</td>
<td>1</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Taylor</td>
<td>[95]</td>
<td>1975</td>
<td>14</td>
<td>7</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>Tsukada</td>
<td>[40]</td>
<td>1975</td>
<td>7</td>
<td>1</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Lee</td>
<td>[41]</td>
<td>1977</td>
<td>9</td>
<td>2</td>
<td>22</td>
<td>0</td>
</tr>
<tr>
<td>Stacy</td>
<td>[96]</td>
<td>1986</td>
<td>13</td>
<td>1</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Bergen</td>
<td>[23]</td>
<td>1989</td>
<td>14</td>
<td>3</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Curtin</td>
<td>[97]</td>
<td>1990</td>
<td>28</td>
<td>6</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Feuer</td>
<td>[20]</td>
<td>1990</td>
<td>15</td>
<td>8</td>
<td>53</td>
<td>0</td>
</tr>
<tr>
<td>Olson</td>
<td>[24]</td>
<td>1991</td>
<td>10</td>
<td>2</td>
<td>20</td>
<td>2*</td>
</tr>
<tr>
<td>Garzetti</td>
<td>[39]</td>
<td>1992</td>
<td>4</td>
<td>1</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Molinie</td>
<td>[101]</td>
<td>1993</td>
<td>29</td>
<td>11</td>
<td>38</td>
<td>0</td>
</tr>
<tr>
<td>Baehrendtz</td>
<td>[102]</td>
<td>1994</td>
<td>21</td>
<td>11</td>
<td>52</td>
<td>3*</td>
</tr>
<tr>
<td>Cotton</td>
<td>[83]</td>
<td>1995</td>
<td>10</td>
<td>3</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Fishman</td>
<td>[93]</td>
<td>1995</td>
<td>14</td>
<td>5</td>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td>Kodama</td>
<td>[14]</td>
<td>1995</td>
<td>10</td>
<td>3</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Kohler</td>
<td>[66]</td>
<td>1996</td>
<td>14</td>
<td>9</td>
<td>64</td>
<td>0</td>
</tr>
<tr>
<td>Tsai</td>
<td>[103]</td>
<td>1996</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Goldblum</td>
<td>[67]</td>
<td>1997</td>
<td>14</td>
<td>4</td>
<td>29</td>
<td>1*</td>
</tr>
<tr>
<td>Scheistroen</td>
<td>[84]</td>
<td>1997</td>
<td>29</td>
<td>8</td>
<td>28</td>
<td>0</td>
</tr>
<tr>
<td>Täggiö</td>
<td>[85]</td>
<td>1997</td>
<td>10</td>
<td>4</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Crawford</td>
<td>[59]</td>
<td>1999</td>
<td>11</td>
<td>5</td>
<td>45</td>
<td>0</td>
</tr>
<tr>
<td>Fanning</td>
<td>[13]</td>
<td>1999</td>
<td>84</td>
<td>30</td>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td>Piura</td>
<td>[104]</td>
<td>1999</td>
<td>3</td>
<td>1</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Parker</td>
<td>[15]</td>
<td>2000</td>
<td>44</td>
<td>16</td>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td>Zollo</td>
<td>[105]</td>
<td>2000</td>
<td>15</td>
<td>5</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Louis-Sylvestre</td>
<td>[110]</td>
<td>2001</td>
<td>49</td>
<td>22</td>
<td>45</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>498</td>
<td>171</td>
<td>34</td>
<td>6*</td>
</tr>
</tbody>
</table>

*Patients progressed to invasive adenocarcinoma during follow-up for intraepithelial vulvar Paget disease.

### Table 4. Vulvar Paget Disease with Stromal Invasion or Associated with Underlying Invasive Adenocarcinoma and Local Recurrence after Therapy (not considered patients lost to follow-up or that refused primary treatment)

<table>
<thead>
<tr>
<th>Author</th>
<th>Ref.</th>
<th>year</th>
<th>No. of cases</th>
<th>No. cases recurred</th>
<th>% Recurrences</th>
<th>No. cases dead of disease</th>
<th>% Dead of disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koss</td>
<td>[39]</td>
<td>1968</td>
<td>2</td>
<td>2</td>
<td>100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Parmley</td>
<td>[106]</td>
<td>1975</td>
<td>7</td>
<td>5</td>
<td>71</td>
<td>5</td>
<td>71</td>
</tr>
<tr>
<td>Taylor</td>
<td>[95]</td>
<td>1975</td>
<td>4</td>
<td>4</td>
<td>100</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>Lee</td>
<td>[41]</td>
<td>1977</td>
<td>4</td>
<td>1</td>
<td>25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Curtin</td>
<td>[97]</td>
<td>1990</td>
<td>5</td>
<td>3</td>
<td>60</td>
<td>2</td>
<td>40</td>
</tr>
<tr>
<td>Feuer</td>
<td>[20]</td>
<td>1990</td>
<td>2</td>
<td>1</td>
<td>50</td>
<td>1</td>
<td>50</td>
</tr>
<tr>
<td>Olson</td>
<td>[24]</td>
<td>1991</td>
<td>6</td>
<td>3</td>
<td>50</td>
<td>1</td>
<td>17</td>
</tr>
<tr>
<td>Baehrendtz</td>
<td>[102]</td>
<td>1994</td>
<td>3</td>
<td>3</td>
<td>100</td>
<td>3</td>
<td>100</td>
</tr>
<tr>
<td>Cotton</td>
<td>[83]</td>
<td>1995</td>
<td>4</td>
<td>1</td>
<td>25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Kodama</td>
<td>[14]</td>
<td>1995</td>
<td>20</td>
<td>10</td>
<td>50</td>
<td>7</td>
<td>35</td>
</tr>
<tr>
<td>Tsai</td>
<td>[103]</td>
<td>1996</td>
<td>2</td>
<td>1</td>
<td>50</td>
<td>1</td>
<td>50</td>
</tr>
<tr>
<td>Goldblum</td>
<td>[67]</td>
<td>1997</td>
<td>5</td>
<td>1</td>
<td>20</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Scheistroen</td>
<td>[84]</td>
<td>1997</td>
<td>5</td>
<td>3</td>
<td>60</td>
<td>3</td>
<td>60</td>
</tr>
<tr>
<td>Täggiö</td>
<td>[85]</td>
<td>1997</td>
<td>6</td>
<td>3</td>
<td>50</td>
<td>2</td>
<td>33</td>
</tr>
<tr>
<td>Crawford</td>
<td>[59]</td>
<td>1999</td>
<td>10</td>
<td>3</td>
<td>30</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Fanning</td>
<td>[13]</td>
<td>1999</td>
<td>16</td>
<td>4</td>
<td>25</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Piura</td>
<td>[104]</td>
<td>1999</td>
<td>2</td>
<td>1</td>
<td>50</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Zollo</td>
<td>[105]</td>
<td>2000</td>
<td>5</td>
<td>3</td>
<td>60</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>130</td>
<td>65</td>
<td>50</td>
<td>31</td>
<td>24</td>
</tr>
</tbody>
</table>
cally directed multiple biopsies, intraoperative intravenous fluorescein with ultraviolet light scanning, and frozen section. All of these techniques have been reported as successful methods and all have limitations [19, 21, 96, 117, 118]. A false-negative rate of approximately 35% in delineating surgical margins is reported for both frozen sections and visual observation [93] because of the presence of irregular boundaries and skip lesions [19, 96]. There is, however, no evidence that intraoperative frozen section margin assessment reduces recurrence or improves survival [93]. Even antibodies to carcinoembryonic antigen, epithelial membrane antigen, and low molecular weight cytokeratins, used to improve Paget cell detection sensitivity, add no value in identifying Paget cells in resection margins that are negative on Paget cell detection sensitivity, add no value in identifying Paget cells in resection margins that are negative on routine hematoxylin and eosin staining [119].

**Recurrences**

The difficulty in defining the margins of vulvar Paget disease lesion extension is closely related to the problem of recurrences: an apparently complete excision of intraepithelial vulvar Paget disease is followed by recurrences, even in skin grafts used to cover the wound after vulvectomy [120]. Patients with recurrent disease are characterized by multiple recurrences [97]. Almost half of the recurrences appear within 18 months from initial treatment [102] with a range from a few months to more than 15 years [13, 15, 83, 101].

Difficulties in comparing reports arise from the different types of surgical procedures performed and from the state of operative margins, which are often not detailed. The recurrence rate of 15–20% in cases with negative margins increases to 50% or more if surgical margins are involved. Furthermore the mean time to recurrence for patients with negative margins is longer than for those with positive margins [14, 15, 59, 93, 101]. The surgical resection of visibly involved skin and mucosa, with visibly normal skin margins of resection, without frozen section assessment, is a reasonable and effective approach to vulvar cutaneous Paget disease [93]. As the frequency of local recurrence is strongly correlated with the presence of invasive disease [15] we reported in separate tables intraepithelial (Table 3) [11, 13–15, 20, 23, 24, 35, 39–41, 59, 66, 67, 83–85, 93, 95–97, 99, 101–105, 110] and invasive (Table 4) [13–15, 20, 24, 39, 41, 59, 67, 83–85, 95, 97, 102–106] vulvar Paget disease series.

Because most recurrences of intraepithelial vulvar Paget disease consist entirely of intraepidermal disease, which does not affect survival [7], and the extent of the initial operation does not correlate with disease recurrence, conservative local excision for intraepithelial lesions is a reasonable consideration in young and old patients.

**CONCLUSION**

The use of biopsies for any unclear vulvar abnormality gives valuable information at a reasonable cost and prevents delay of diagnosis. When diagnostic difficulty occurs, immunohistochemical studies can be used. The recently proposed vulvar Paget disease subclassification will contribute to the correct diagnosis and appropriate treatment for affected patients. Prognosis is closely related to pathologic characteristics of the disease. Additional molecular genetic studies are needed to better understand the biological behavior of vulvar Paget disease.

**Acknowledgments**

The authors thank Professor Rainer Kürzl (Department of Gynecology and Pathology, Frauenklinik University of Munich, Germany) for critical revision of the first version of the manuscript and Doctor Sebastiana Privitera (Department of Pathology, St. Anna Hospital, Turin, Italy) for providing histologic photographs.

**REFERENCES**


